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Introduction 
Early History of Papillomaviruses (PVs) 
Research concerning PVs began in the mid-19th century. In 1842, an Italian 
physician, Dr. Domenico Antonio Rigoni-Stern, noticed that married women and 
prostitutes developed cervical cancer, but nuns did not. This was the first indicator that 
cervical cancer could be sexually transmitted. However, it’s cause was not determined at 
that time 1. In 1907, Another Italian physician, Giuseppe Ciuffo, showed that cell-free 
filtrate from ground-up genital and non-genital warts was able to transmit both genital 
and non-genital warts 2. In 1933, Shope and Hurst showed that soluble extracts from non-
genital warts from wild cottontail rabbits contained a transmissible agent. This agent was 
able to cause similar warts in healthy rabbits when it was injected under their skin. Shope 
and Hurst correctly deduced that these warts were caused by a virus 3. In 1935, Rous and 
Beard showed that cottontail rabbit papillomavirus called (CRPV) could cause skin 
cancer in rabbits. After exposure to the extract for an extended time period, skin cancer 
was detected instead of warts. Since CRPV has a DNA genome, it represented the first 
known DNA tumor virus 4. In 1972, Jablonska and Orth were the first researchers to 
discover the connection between human papillomavirus (HPV) and skin cancer 5.  In 
1976, zur Hausen published the hypothesis that HPV instead of herpes virus plays an 
important role in the causation of cervical cancer 6. Other scientists rejected this theory 7. 
In 1983 and 1984, zur Hausen proved his theory by identifying HPV 16 and HPV 18 
DNA in cervical tumors. In 2008, he received the Nobel Prize for this research 8 . By 
2006, two HPV vaccines, Gardasil and Cervarix, had been developed for the prevention 
of genital warts and cervical cancer. 
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Human papillomaviruses (HPV) 
HPVs are non-enveloped DNA tumor viruses with small (approximately 8 kb) 
circular double stranded genome (Figure 1). Despite their small genome, they encode for 
8 genes (six early (E) genes and two late (L) genes). The HPV genome is organized in 
three regions:  
1) Early genes which are: E6 and E7 (oncoproteins), E1 (DNA helicases involved 
in DNA viral replication), E2 (Viral DNA replication), E4 (may play a role in 
viral escape from cornified cell envelope) and E5 (involved in genome 
amplification)  
2) Late genes: L1 (major capsid protein) and L2 (minor capsid protein)  
3) Long Control Region (LCR): non-translated region and major regulatory region   
for HPV life cycle.     
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C.M D Abramo and J Archabault 2011 Open 
Virol J 
 
Figure 1: Diagram of HPV genome.  Notice that this genome is composed of three 
regions: 1) Early genes E6, E7, E1, E2, E4 and E5. 2) Late genes L1 and L2 and 3) LCR 
region. 
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HPV classification 
HPVs are divided among 4 major groups (alpha, beta, gamma and delta). HPV 
types in the genus alpha-papillomaviruses are associated with mucosal and cutaneous 
lesions in human and primates. HPV types within this genus share a conserved sequence 
within an open reading frame (ORF) of the E5 gene 9. Group alpha is divided into 15 
species (1-15) based on the homology of L1 sequence 10.   Each of these species contains 
many HPV types, grouped by diversity of their E6 and E7 gene sequences. More than 
150 HPV types have been completely sequenced. 
HPVs that primarily infect genital epithelial tissues are sexually transmitted. 
Infection can result in a wide range of epithelial tissue anomalies including genital warts and 
cervical cancer.  HPV types associated with cervical cancer are known as high risk (HR) 
types (for example, HPV types 16, 18, 52, and 59), while those associated with genital warts 
are known as low risk (LR) types (for example HPV types 6 and 11).  
Low Risk HPV types (LR-HPV) 
  Known as non-oncogenic HPV types, these HPV types may cause benign or low-
grade abnormalities of cervical cells and anogenital warts known as condylomata 
acuminata. HPV types 6 and 11 are found in more than 90% of condylomata acuminata 
11.   
High Risk HPV types (HR-HPV) 
  HR-HPV types or oncogenic HPV types are associated with intraepithelial 
neoplasia of the anogenital region, including cervical, vulvar, vaginal, penile, and anal 
cancers as well as some oropharyngeal cancers. These HPV types 16, 18, 31, 33, 35, 52, 
58, 67, 56, 56, 59, 39, 45, 66, 68, and 70 are associated with malignant mucosal lesions. 
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Among these HPV types, eight (16, 18, 45, 33, 31, 52, 58, and 35) are the most common 
HPV types found in anogenital cancers 12. These eight HPV types are also found in 90 % 
of cervical cancer worldwide. The HPV types 16, 33, 31, 52, 58, and 35 are grouped as 
HPV species nine (designated A9); while HPV types 18 and 45 form HPV species seven 
(designated A7). Both species nine and seven are in the genus alpha-papillomavirus.  
 
        Proportion of cervical cancer caused by the carcinogenic HPV types 
 
 Proportion of cervical  
cancers caused 
Cumulative 
total 
   
HPV16 54·6% 54·6%     
HPV18 15·8% 70·4%     
HPV33   4·4% 74·8%     
HPV45   3·7% 78·5%     
HPV31   3·5% 82·0%     
HPV58   3·4% 85·4%     
HPV52   2·5% 87·9%     
HPV35   1·8% 89·7%     
HPV59   1·1% 90·8%     
HPV56   0·8% 92·2%     
HPV51   0·7% 92·9%     
HPV39   0·7% 93·6%     
HPV73   0·5% 94·1%     
HPV68   0·5% 94·6%     
HPV82   0·2% 94·8%     
No type 
identified 
  5·2% 100%     
Adapted from Schiffman et al (2007), LANCET 
 
Table 1: Proportion of cervical cancer caused by carcinogenic HPV types. Notice that 
HPV 16/18 cause more than 70% of cervical cancer. 
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HPV life-cycle from infection to cervical cancer 
Proliferative and persistent phase 
The proliferative life cycle of HPV begins when viruses are deposited on the surface 
of the mucosal epithelium of the genitals, anus, mouth, or airways through sexual contact 13. 
HPV virions then pass into the basal layer of the stratified epithelium through microscopic 
breaks; alternatively the virions may directly infect the columnar cells that form the basal 
layer of the epithelium of the transformation zone, which is the area adjacent to the border of 
endocervix and ectocervix 13-15. The virions then enter into the epithelial cells via an 
endosome by binding to heparan sulphate proteoglycans in the basement membrane. Once 
in the epithelial cells, the virions are transported spatially through early and late endosomes. 
In the late endosome, the virions are uncoated and delivered into the nucleus. In the nucleus 
with the help of the host’s transcription machinery, the HPV genome early promoter p97 is 
activated leading to transcription of early viral genes E6 and E7. The E6 and E7 proteins 
bind to the host cell cycle control proteins causing the host cell to progress to S phase, and to 
retard normal terminal differentiation. The first phase of viral genome replication then 
occurs 16,17. Once the host cell divides and segregates into two daughter cells, one infected 
daughter cell remains in the basal layer, and the other migrates away from the basal layer 
and starts the differentiation process 18. During the differentiation process, E1, E2, E4 and 
E5 genes are expressed and the viral genome continues to replicate. Once the infected cell 
reaches terminal differentiation, the late genes L1 and L2, coding for viral capsid proteins, 
are expressed. The new virus particles are then packaged and released from the dead cells. 
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Persistence and integration phase 
Persistent HPV infection with high risk types, such as HPV 16 and 18, is one of the 
most important events leading to the development of cervical cancer 19. In addition, HPV 
integration is also considered an important event leading to the progression from pre-
neoplastic lesions to invasive carcinoma 20. Our previously published data demonstrated that 
the integration of HPV 59 genome into the host chromosome was a major event that led to 
the immortalization of human foreskin of epithelial cells 21. DNA integrates into the host cell 
genome within the viral E2 gene. The mechanism of HPV double strand DNA break is not 
yet known. However, there are some chromosomal sites known as fragile sites, where HPV 
integration is more likely to occur. It is hypothesized that as chromosome breaks occur, this 
allows for integration of viral DNA. In some cases, the HPV genome (particularly HPV 18) 
integrates near proto-oncogenes such as C-myc, which are associated with cellular 
proliferation. As a result, this integration perturbs the function of affected proto-oncogenes 
which may promote the development of cancer 22. However, one study speculated that 
reactive oxygen species generated from cervical inflammation, due to HPV infection, maybe 
responsible 23. Moreover, integration occurs at multiple sites within the human genome; this 
would suggest that the integration occurs randomly 24.  
Diseases associated with HPV 
Linkage between HPV and cervical cancer was established through many 
epidemiological studies in which nearly all cervical cancer cases were attributable to 
HPV infection 25,26. Moreover, percentage of other non-cervical cancers was attributable 
to HPV infection as well, such as 12%–63% of oropharyngeal cancer, 90%–93% of anal 
cancers, 36%–40% of penile cancers, 40%–64% of vaginal cancers, and 40%–51% of 
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vulvar cancers 27. In addition to cancer, HPV is responsible for all genital warts. HPV 
types 6 and 11 have been associated with 90 % of genital warts.  
Major cervical cancer types 
Major cervical cancer types comprise squamous cell carcinoma (SCC) and 
adenocarcinomas (AC). SCC is the most common cervical cancer histological type 
detected in 70% to 75% of cervical cancers 28. HPV 16 type causes the majority of SCC. 
AC cervical cancer type makes up 5% to 10% of cervical cancers. HPV 18 is usually 
found in AC. Also, there are other types of cervical cancers accounting for 15% of 
cervical cancers, such as lymphoepithelioma and papillary squamous carcinomas.  
1- Examples of normal cervix compared to cervical cancer  
  
     Panel (A)                           Panel (B)                                Panel (C) 
 
Figure 2: Clinical samples of a normal cervix on the right in panel (A) and cervical 
cancer (B and C). 
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Panel A (Normal cervix (50 X))         Panel B (Cervical cancer (50 X)) 
Figure 3: Normal cervix compared to cervical cancer H&E. In Panel A there is nice 
separation between the normal cervical epithelium and the myometrium. However, in the 
cervical cancer section there is invasion of the myometrium and there is no organization 
to the epithelium. 
 
HPV vaccine 
Though the incidence of cervical cancer has declined in developed countries due 
to certain public health measures, it still has a profound impact on women living in 
developing countries. Implementation of HPV vaccine program in these countries can 
reduce the burden of HPV associated diseases, such as cervical cancer.  Currently, there are 
two FDA approved HPV vaccines, Gardasil and Cervarix. Both vaccines contain empty 
HPV virus particles called virus-like particles (VLP). These VLPs are non-infectious, and 
are prepared from the L1 protein using recombinant DNA technology. Gardasil (Merck, 
Whitehouse Station, NJ) is a quadrivalent (prevents from 4 HPV types) vaccine. It is 
approved first for girls and women 9-26 years of age and later for males 9-26 years of age 
29 . Gardasil prevents cervical pre-cancers, genital warts and anal pre-cancers caused by 
HPV types 6, 11, 16, and 18. Cervarix (GlaxoSmithKline, Research Triangle Park, NC), 
is a bivalent vaccine, and is approved for girls and women 9-25 years of age to prevent 
9 
 
cervical cancer caused by HPV types 16 and 18. The CDC highly recommends that 
preteens be vaccinated long before the start of sexual activity. Furthermore, for optimal 
result, individuals should receive all three doses. It had been suggested that HPV vaccine 
can offer certain degree of cross-protection against HPV types that are related to HPV 16 
and 18 30. However, cross-protection against HPV types such as HPV 31, 33 and 45 is not 
robust, is short lived, and the clinical importance of such cross-protection is not known 31.  
HPV research in Dr. Brown’s laboratory 
The World Health Organization (WHO) classifies cervical cancer as the second 
most common cancer in women globally 32 . This type of cancer is responsible for more 
mortality in women than any other cancer in developing countries. The outcome of 
hundreds of epidemiological studies helped the scientific community understand HPV 
infection. Such studies helped develop guidelines for cervical cancer prevention 
strategies, including vaccination. Several HPV epidemiologic studies performed in our lab 
contributed to the understanding of cervical cancer; some of these studies are summarized 
below.  
• Distribution of human papillomavirus types in cervicovaginal washings from 
women evaluated in a sexually transmitted diseases clinic 33. 
This study demonstrated that many HPV types were associated with cervical 
dysplasia, including LR-HPV types. Brown et al. also showed that HPV was common 
among women attending an STD clinic.  
• A longitudinal study of genital human papillomavirus infection in a cohort of 
closely followed adolescent women 34. 
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This study found that the detection of HPV in sexually active adolescent women was 
extremely high, multiple HPV types were identified in this population and the persistence of 
this infection frequently resulted in cervical dysplasia. 
• Association of condom use, sexual behaviors, and sexually transmitted 
infections with the duration of genital human papillomavirus infection among 
adolescent women 35.  
This longitudinal study involving only adolescent women confirmed the relationship 
between HPV infection, condom use and the number of sexual partners. Less frequent 
condom use and a greater number of sexual partners were associated with longer periods of 
HPV DNA detection (HPV persistence).  
• Detection of specific human papillomavirus types in paraffin-embedded sections 
of cervical carcinomas 36 
In this study we were able to type HPV from paraffin-embedded sections of cervical 
cancer archived tissues with sensitivity similar to that found in studies using fresh tissues. 
HPV 16 was the most commonly detected HPV type. Also, using DNA in-situ 
hybridization, we concluded that in most cases HPV was integrated into the host genome.  
• Human papillomavirus genotypes associated with cervical cytologic 
abnormalities and HIV infection in Ugandan women 37 
In this study we found a high prevalence of HPV in cervical swabs among HIV 
positive Ugandan women. In addition to HPV types 16, 52 and 58 were also highly detected. 
In this study we also found that HR-HPV types were associated with abnormal Pap smear in 
HIV women. 
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• Human papillomavirus infection and its association with cervical dysplasia in 
Ecuadorian women attending a private cancer screening clinic 38 
This study contributed to the understanding of HPV prevalence and distribution in 
swabs from Ecuadorian women. HR-HPV types 16, 52, 58 and 59 and LR-HPV types 62, 
71, 72, and 83 were the most common HPV types found in this population. Furthermore, 
there was a strong correlation between the HPV types found in vaginal swabs and cervical 
swabs. However, vaginal swabs tended to have additional HPV types compared to cervical 
swabs. 
• Human papillomavirus detection and typing in thin prep cervical cytologic 
specimens comparing the Digene Hybrid Capture II Assay, the Roche Linear 
Array Genotyping Assay, and the Kurabo GeneSquare Microarray Assay 39 
In this study we compared three assays for HPV detection; the Roche Linear Array 
Genotyping Assay (LA), the Digene Hybrid Capture II Assay (HC), and the Kurabo 
GeneSquare Microarray Assay (GS). We found high agreement between LA and GS. 
• Natural history of multiple human papillomavirus infections in female 
adolescents with prolonged follow-up 40 
This prolonged follow-up study of adolescent women, provided insight into the 
natural history of HPV infection. Participants were followed for approximately 7 years. All 
study subjects tested positive for HPV at least one time during the course of the study. 
Additionally, most participants tested positive for HPV 16 or HPV 18 (most common HPV 
types in cervical cancer). 
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Rational 
Importance of this study 
The current HPV vaccines prevent infection and disease from two HR-HPV types 
(16 and 18). However, the prevalence of HPV types in cervical cancer may differ 
between geographic regions. Knowing the prevalence of these HPV types in cervical 
cancer from certain geographic regions may emphasize the need for a vaccine that covers 
a greater number of HPV types.  
In this study we compared the distribution of HPV types in cervical cancer 
specimens from women living in either Indiana or Botswana. We selected these two 
regions because of many variations between Indiana and Botswana including 
geographical, cervical cancer incidence and HIV/AIDS prevalence. 
Cervical cancer is the second most frequent cancer in Botswana with an incidence of 60 
per 100,000 women per year 41,42. Cervical cancer is the second most deadly form of 
cancer in women living in Botswana, with as many as 14.8 deaths per 100,000 women 
per year 43. The most common HPV types in women with invasive cervical cancer in 
Botswana were HPV 16 (52.1 %), HPV 18 (10.7%), HPV 33 (9.1%), HPV 31 (4.3%), 
HPV 45 (3.3%), HPV 59 (2.0%), HPV 35 (1.7%), HPV 58 (1.2%), HPV 52 (0.8%) and 
HPV 6 (0.4%). Many factors are responsible for the high prevalence of cervical cancer in 
Botswana. High incidence of HIV infection is one of these factors. Botswana has a high 
rate of HIV/AIDS infection 23.4% among females 44-46.   
Cervical cancer ranks 14th of all cancers in the United States 47. Cervical cancer 
incidence rate was 7.4 cases per 100,000 women per year41. The mortality rate was 2.7 
deaths per 100,000 women per year. This low cervical cancer incidence in Indiana is 
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largely due to the wide-scale implementation of cytological screening programs utilizing 
the Papanicolaou (Pap) test, HPV vaccination, and low incidence of HIV/AIDS. Indiana 
has lower HIV/AIDS infection 0.7 % among females compared to Botswana 45.   
Objectives 
In this study we isolated DNA from formalin-fixed and paraffin-embedded 
cervical cancer specimens from Indiana and Botswana. By using this direct method, 
known as thin-section PCR, we were able to determine the actual HPV type contributing 
to cervical cancer. Most of previous studies of HPV type distribution in cervical cancers 
used cervical swabs to determine HPV types in cancers. Because cervical swab 
specimens sample a large area and can contain HPV types in addition to the types causing 
cervical cancer, it is difficult, and sometimes impossible to determine which type is 
responsible for the cancer. This has led to confusing and inconsistent results. 
 The aims of this thesis are to: 
• Design a standardized protocol for high quality DNA extraction from archived 
paraffin embedded tissues (FFPE) cervical tissue 
• Determine and compare HPV type distribution in cervical cancers in 
Botswana and Indiana.  
• Evaluate the association of cervical cancer and HIV infection in women living 
with HIV in Botswana. 
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Hypothesis 
• High quality DNA (less PCR inhibitors and high molecular weight amplifiable 
DNA) can be extracted from FFPE cervical cancer tissues and successfully 
amplified by PCR. 
• HPV typing can be performed successfully on FFPE. 
• HPV type distribution in cervical cancers will differ between Botswana and 
Indiana. 
• Differences in HPV type distribution will be explained by HIV infection. 
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Materials and Methods 
Acquisition of cervical cancer 
FFPE cervical cancer blocks were obtained from women residing in Indiana 
(United States) and Gaborone (Botswana).  Fifty-one cervical cancer blocks were 
obtained from 51 women treated at Indiana University School of Medicine (IUSM), and 
214 cervical cancer blocks from 214 women treated at the STD clinic in Gaborone in 
Botswana. Cervical cancer tissues from Indiana were archived during 2008 through 2011 
and the age of cervical cancer tissues from Botswana were collected between 2009 and 
2010. These specimens had been fixed with formalin and embedded in paraffin at the 
local sites. Because the Botswana blocks were disintegrating from paraffin dehydration, 
we decided to re-embed the blocks in new paraffin prior to sectioning.   
Histology and pathology classification 
All sections were prepared at IUSM. Blocks were cut on a Reichert-Jung 
microtome at a thickness of 5 microns with a clean blade utilized for each tissue. Cut 
sections were then placed on positively charged slides.  Twenty sections were cut for 
each tissue, and the first and last sections were stained with hematoxylin and eosin (H&E 
stain). Examination of each H&E stain was performed under light microscope (Olympus 
BX 41). Specimens with no or small epithelium (less than 5% of the total section) were 
eliminated from this study. Also, H&E stains were used for pathology classifications. All 
cancer precursor lesions were eliminated from this study and only invasive cervical 
cancers were used in this study. The invasive cervical cancers were classified as 
squamous cervical cancer (SCC) or adenocarcinomas (AC).  
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Macro-dissection 
H&E stained slides were examined under light microscope for cancerous 
epithelium to healthy connective tissue ratio. In some sections, there was much more 
healthy connective tissue present than was cancerous epithelial tissue. Since the HPV 
genome would only be found in the cancerous epithelium tissue, a higher abundance of 
human DNA in healthy tissue may reduce the sensitivity of the HPV assay used. To avoid 
this problem, macro-dissection was used to reduce the amount of healthy connective 
tissue. 
In each section new blades (Blades single edge from Fishers, cat# 12640) were 
used to Macro-dissect unstained slides. The cancerous epithelium was identified under a 
light microscope and separated from the surrounding healthy connective tissue as shown 
in Figure 4.           
 
Figure 4: Macro-dissection performed on one of Botswana cervical cancer case 
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DNA extraction from tissue sections 
Deparafinazation 
Most of these protocol steps were adopted from a published protocol with some 
modifications 36. In a laminar flow hood, 4 to 6 sections of paraffin embedded slides were 
carefully scraped from the glass slides with new blade (sigma-Aldrich cat# 296988), 
using 1 mL octane (this step was adapted from Gregory Buzard online protocol) 48 ( the 
recovered sections were then c into a labeled 2 mL sterile screw-capped tubes). Samples 
were rocked at room temperature for 10 minutes (min) and centrifuged at 15.000 x g for 
10 min in a micro-centrifuge (Labnet Z 233 M2). The octane was then gently removed, 
without disturbing the pellet.   Then, 500 uL fresh octane was added to the pellet and the 
tubes were capped and rocked for an additional 5 min to dissolve any remaining paraffin. 
The samples were centrifuged 19.000 x g for 5 min. The octane was again gently pipetted 
off without disturbing the pellet. One mL of absolute ethanol was added to the pellet; the 
tubes were capped and inverted to mix the pellet with ethanol, followed by centrifugation 
for 10 minutes at 19.000 x g. The ethanol was carefully removed and 500 uL of fresh 
absolute ethanol was added. The tubes were then centrifuged for 10 minutes at 19.000 x 
g. The ethanol was carefully removed and the open tubes were spun in a Speed Vacuum 
(Savant) for 20 min to dry.  
Overnight Digestion 
The resulting dried pellets were then suspended in 300 uL Specimen Transport 
Medium (STM, QIAGEN) with 200 ug proteinase K buffer (from QIAamp MinElute 
Media Kit).   Samples were vortexed for 10 s (seconds) and incubated in a dry heat block 
at 55˚C (degree Celsius) for 12 to 16 hours. 
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DNA extraction 
Twelve to 16 h later, DNA was extracted from the samples using the QIAamp 
MinElute Media Kit (Qiagen, Germantown, MD, USA) according to the manufacturer’s 
instructions. 
DNA spectrophotometry 
DNA concentration was determined by spectrophotometry (Beckman DU-64, 
Beckman Coulter, Brea, CA) and approximately 200 ng was used for each PCR reaction. 
For samples in which the OD 260/280 ratio was less than 1.8, additional slides were used 
to re-extract DNA. 
DNA Amplification and Genotyping 
DNA Amplification 
Using the LINEAR ARRAY HPV Genotyping Test (LA-HPV) (Roche, 
Indianapolis, IN, USA) HPV DNA was PCR amplified using two sets of biotinylated 
primers, PGMY09 / PGMY11. This Genotyping KIT specifically amplifies the 
polymorphic HPV L1 region of 37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 
45, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 
IS39, and CP6108), the resulting PCR product is approximately 450 base pairs long. 
Additionally, this assay includes PCR system control primers BPCO4 / BGH20 specific 
for human beta-globin.  
DNA template (200-300 ng) was mixed with LA-HPV Master Mix (MMX) and 
HPV Magnesium Solution, Reactions were subjected to 1 cycle at 50˚C for 2 min, 1 cycle 
at 95˚C for 9 min (denaturation), then 40 cycles of:  95˚C for 1 min (denaturation), 55˚C 
for 1min (annealing), 72˚C for 1 min (extension), followed by 1 cycle at 72˚C for 5 min 
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(final extension) in a Perkin-Elmer 9600 thermal cycler. Reactions were subsequently 
maintained at 72˚C and 10 uL of PCR product was analyzed on 1.8% agarose gels as 
shown in Figure 5. Samples were then stored at -80˚C. 
 
M: marker, (-) negative control, (+) positive control, (1 and 2) Botswana cervical cancers cases 
 
Figure 5: Agarose gel (1.8 %) electrophoresis of PCR product of HPV and beta-globin 
amplification 
 
HPV Genotyping 
PCR reactions, including positive and negative controls were analyzed by LA-
HPV according to manufacturer’s instructions. PCR products were denatured and 
incubated with LA-HPV Genotyping Strips. Then, biotin-labeled amplicons were 
hybridized to the matching sequence of the immobilized probes. Genotyping Strips were 
washed and incubated in Streptavidin-Horseradish Peroxidase Conjugate (SA-HRP) 
buffer. Genotyping Strips were washed to remove unbound SA-HRP. Genotyping Strips 
were incubated with peroxidase conjugate and solution containing hydrogen peroxide and 
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tetramethylbenezidine (TMB). SA-HRP catalyzes the oxidation of TMB to form a blue 
colored complex as shown in Figure 6.  
Quantitative evaluation of 37 types of HPV was made by visually comparing band 
intensity against two concentrations (high and low) of human beta-globin control probes 
on each strip. 
 
(-) negative control, (+) positive control, (1 and 2) Botswana cervical cancer cases 
 
Figure 6: HPV Genotyping using Roche Line Blot Assay 
HIV Amplification and Detection 
HIV Amplification 
HIV was amplified by PCR from paraffin-embedded tissue using two sets of 
primers SK145- M (5’-GGG ACA TCA AGC CAT GCA AAT-3’) and SK431-M (5’-
TGC TAT GTC AGT TCC CCT TGG TTC TCT-3’). This set of primers was referenced 
in Ciardi’s paper 49 and modified in our laboratory. We removed six nucleotides from 5’ 
end of SK145 primer to overcome the difference in GC content between this primer set. 
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These primers were used to amplify specifically a portion of 142 base pairs (bp) of HIV 
gag gene (1360-1507). The plasmid pMDLg/pRRE was provided by Dr K. Cornetta 
(IUSM)in which complete HIV gag and pol genes are inserted, was used for primer 
optimization and as a positive control.   
DNA template (200-300 ng) was mixed with 25 uL of Master Mix (MMX) 
FastStart kit (Roche, Indianapolis), 3 uM downstream and upstream primers and sterile 
double distilled water for a total volume of 50 uL. Reactions were subjected to 1 cycle at 
94˚C for 9 min, then 40 cycles of: 94˚C for 30 S (denaturation), 55˚C for 30 S 
(annealing), 72˚C for 30 S (extension), followed by 1 cycle at 72˚C for 7 min (final 
extension) in a Mastercycler ProS (Eppendorf, Humburg, Germany).  
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HIV Detection 
PCR products, including positive and negative controls were analyzed on 1.8% 
agarose gels as shown in Figure 7. Two PCR products were sequenced. Samples with 150 
bp bands were purified from agarose gels using QIAquick kit (Qiagen, MD, USA), 
according to the manufacture’s protocol. Purified PCR products were then sequenced in 
the IUSM core DNA facility. Homology of the sequenced samples was determined using 
the Basic Local Sequencing Alignment Search Tool (BLAST) search at NCBI. 
 
(-) negative control, (+) positive control,  (1-2)  Botswana cervical cancer cases 
 
Figure 7: Agarose gel (1.8 %) electrophoresis of HIV gag gene amplicon 
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Results 
Statistical analysis 
Beta-globin positivity among all cervical cancer specimens and HPV positivity 
among beta-globin-positive samples were compared between Indiana and Botswana 
samples. Type specific HPV detection was compared between Indiana and Botswana 
HPV positive samples. Prevalence of Alpha 9 and Alpha 7 types between Indiana and 
Botswana were also compared. Additionally, HPV detection was compared between HIV 
positive and negative specimens among Botswana samples. Comparisons were made 
using Fisher’s exact tests or Chi-square tests as indicated in the specific table. All 
analyses were performed in the Department of Biostatistics, Indiana University School of 
Medicine, using SAS (Version 9.3, Copyright©2012 SAS Institute Inc., Cary, NC).  
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Accounting Table 
Overall, 214 FFPE cervical blocks were received from the Women’s clinic in 
Gaborone in Botswana and 51 FFPE cervical blocks were received from Wishard Hospital, 
IUSM, Indiana. FFPE cervical blocks with small or no epithelium and/or pre-cancer were 
excluded from this study.   Of the 214 FFPE cervical blocks received from Botswana, 32 
were excluded from this study (26 had no epithelium and 6 were pre-cancerous lesions) 
(see Table 2). All 51 FFPE cervical blocks received from Indiana fit the criteria of this 
study (Table 2).  
 
Study sites Indiana Botswana 
Cases received 51 214 
Cases with adequate 
epithelium 
 
Cervical cancer cases  
51 
51 
188 
182 
Cases with detected beta-
globin 
 
Cases with detected HPV 
50 
46 
171 
136 
 
Table 2: Summary of cervical cancer cases from Botswana and Indiana 
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Histology and pathology classification 
H&E sections from all cervical cancer blocks from both sites were examined by 
Drs. Darron R. Brown, Harvey Kramer or Helena Spartz (Indiana University School of 
Medicine). Sections were examined for epithelial tissue content and pathologically 
classified. They were classified either as SCC or AC. All 50 cervical cancer specimens 
from Indiana were classified as SCC, and 166 from Botswana were SCC and 5 were AC 
(Table 3). 
 
Study site  Indiana (n=50) Botswana (n=171) 
¹SCC 50 166 
²AC 0 5 
¹Squamous cervical cancer 
²Adenocarcinoma 
 
Table 3: Pathology classification of Indiana and Botswana cervical cancers 
 
Macro-dissection 
Macro-dissection was used to reduce healthy connective tissue in cases where 
more healthy connective tissue was present than cancerous epithelial tissue. Of 182 
Botswana cervical cancer cases, 51 cases were macro-dissected and of 50 Indiana 
cervical cancer cases, 17 cases were macro-dissected.  
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DNA extraction from tissue sections 
Adequacy of extracted DNA was determined by the amplification and detection 
of the human beta-globin gene. Samples were included in the analyses if human beta-
globin gene was detected by reverse blot strip assay.  Beta-globin was amplified in 171 of 
182 (94.0%) cervical cancer specimens from Botswana, and 50 of 51 (98.0%) cervical 
cancer specimens from Indiana. The difference in adequate DNA extracted from 
Botswana specimens and Indiana specimens was not statistically significant (p<0.472) as 
shown in Table 4.  
Study site Indiana (n=51) Botswana (n=182) p-value 
¹BG positive cases   50 (98.0%)   171 (94.0%) ²P<0.472 
¹ Beta-globin ² Chi-Square test 
Table 4: DNA adequacy results of cervical cancer cases from Indiana and Botswana. 
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HPV genotyping 
HPV positivity 
All adequate samples were tested for 37 HPV types as described in the Methods 
section. HPV of any type was detected in 46 of 50 (92.0%) cervical cancer specimens 
from Indiana, and 136 of 171 (79.5%) cervical cancer specimens from Botswana (Table 
5). The difference in HPV DNA detection was statistically significant (p=0.042) (Table 
5). 
Study site Indiana  
(n=50) 
Botswana 
(n=171) 
p-value 
HPV-positive/BG² 
positive 
46 (92.0%) 136 (79.5%) ¹P=0.042 
 ²Beta-globin , ¹Chi-Square test 
Table 5: Indiana and Botswana HPV-positive cervical cancer cases 
HPV type distribution 
Overall, HPV 16 was the most common HPV type in cancers from both sites, 
detected in 40 of 46 (80.0%) HPV-positive cervical cancer specimens from Indiana and 
58 of 136 (42.9%) HPV-positive cervical cancer specimens from Botswana (p<0.001) 
(Table 6). The second most frequently detected HPV type in both sites was HPV 18, 
detected in 4 of 46 (8.7%) HPV-positive cervical cancer specimens from Indiana and in 
32 of 136 (23.5%) HPV-positive cervical cancer specimens from Botswana.  The 
difference in HPV 18 detection between cervical cancer specimens from Indiana and 
Botswana was statistically different (P=0.029) (Table 6).  
We detected a greater number of HPV types other than HPV types 16 or 18 in 
cervical cancer specimens from Botswana than in cervical cancer specimens from Indiana 
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(Table 6 and Figure 8).  We detected only 3 HPV types other than HPV types 16 or 18 
HR-HPV types in cervical cancer specimens from Indiana and they were HPV types 31, 
33 and 45 (Table 6). Individually, HPV types other than HPV types 16 or 18 did not 
differ significantly between cervical cancer specimens from Indiana and Botswana (Table 
6). 
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 1 Fisher’s exact test 
2 Chi-square test  
 
Table 6: HPV type prevalence and distribution in beta-globin and HPV-positive cervical 
cancer specimens from Indiana and Botswana 
 
HPV Type Indiana (n=46) Botswana (n=136) p-value 
  High-risk Type Distribution  
HR-HPV  46 (100%) 130 (95.6%) p=0.3401 
HPV 16 40 (87.0%) 58 (42.7%) p<0.001
2 
HPV 18 4 (8.7%) 32 (23.5%) p=0.0292 
HPV26 0 5 (3.7%) p=0.3321 
HPV31 1 (2.2%) 5 (3.7%) p=1.0001 
HPV33 1 (2.2%) 7 (5.2%) p=0.6821 
HPV35 0 8 (5.9%) p=0.2051 
HPV39 0 6 (4.4%) p=0.3401 
HPV45 3 (6.5%) 12 (8.8%) p=0.7641 
HPV51 0 3 (2.2%) p=0.5731 
HPV52 0 4 (2.9%) p=0.5741 
HPV53 0 1 (0.7%) p=1.0001 
HPV58 0 2 (1.5%) p=1.0001 
HPV59 0 2 (1.5%) p=1.0001 
HPV66 0 4 (2.9%) p=0.5741 
HPV67 0 1 (0.7%) p=1.0001 
HPV68 0 2 (1.5%) p=1.0001 
HPV69 0 1 (0.7%) p=1.0001 
HPV82 0 2 (1.5%) p=1.0001 
  Low-risk Type Distribution  
LR-HPV  0 12 (8.8%) p=0.0391 
HPV6 0 1 (0.7%) p=1.0001 
HPV11 0 1 (0.7%) p=1.0001 
HPV40 0 1 (0.7%) p=1.0001 
HPV55 0 1 (0.7%) p=1.0001 
HPV81 0 1 (0.7%) p=1.0001 
HPV83 0 2 (1.5%) p=1.0001 
HPV84 0 6 (4.4%) p=0.3401 
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Figure 8: Figure illustrating HPV type prevalence and distribution in beta-globin and 
HPV-positive cervical cancer specimens from Indiana and Botswana. 
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HPV distribution in adenocarcinomas (AC) 
A total of 5 AC specimens were obtained from Botswana; no cancers from 
Indiana were AC. HPV type distribution in the 5 AC specimens from Botswana were as 
follows (Table 7): HPV 18 in 2 of 5 (40.0%), HPV 16 in 1 of 5 (20.0%), HPV 26 in 1 of 
5 (20.0%), and no HPV detected in one cancer.  
HPV types  Botswana (n=5)  
HPV 18 
HPV 16 
HPV 26 
No HPV 
2 (40 %) 
1 (20 %) 
1 (20%) 
1 (20%) 
 
Table 7: HPV type distribution in adenocarcinomas from Botswana 
HPV distribution by groups 
HPV types were divided into groups (non-HPV 16/18, non-HPV 16/18 HR, A9, 
non-HPV 16 A9, A7, non-HPV 18 A7, and LR-HPV). We conducted statistical analysis 
to investigate HPV distribution by groups among HPV positive cervical cancer 
specimens from both sites.  
Non-HPV 16/18 types were detected in 5 of 46 (10.9%) cervical cancer 
specimens from Indiana and 65 of 136 (47.8%) cervical cancer specimens from Botswana 
(p <0.001) (Table 8).  Non-HPV 16/18 HR types were detected in 5 of 46 (10.9%) 
cervical cancer specimens from Indiana and 56 of 136 (41.2%) cervical cancer specimens 
from Botswana (p<0.001) (Table 8). A9 HPV types were detected in 41 of 46 (89.1%) 
cervical cancer specimens Indiana and 79 of 136 (58.1%) detected in Botswana cervical 
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cancer (p<0.001) (Table 8).  Non-HPV 16 A9 types were detected in 2 of 46 (4.4%) 
cervical cancer specimens from Indiana and 26 of 136 (19.1%) cervical cancer specimens 
from Botswana (p<0.016) (Table 8).   
A7 HPV types were detected in 7 of 46 (15.2%) cervical cancer specimens from 
Indiana and 49 of 136 (36.0%) cervical cancer specimens from Botswana (p<0.001) 
(Table 9).  Non-HPV 18 A7 types were detected in 3 of 46 (6.5%) cervical cancer 
specimens from Indiana and 18 of 136 (13.2%) cervical cancer specimens from Botswana 
(p<0.218) (Table 8). 
 
HPV Groups Indiana Botswana p-value 
HPV 46 136  
HR-HPV ³  46 (100 %) 130 (95.6 %) ¹P=0.340 
Non-HPV 16/18 5 (10.9 %) 65 (47.8 %) ²P<0.001 
Non-HPV 16/18 HR 5 (10.9 %) 56 (41.2 %) ²P=0.001 
⁴A9 41 (89.1 %) 79 (58.1 %) ²P=0.001 
Non-HPV 16 A9 2 (4.4 % 26 (19.1 %) ²P=0.016 
⁵A7  7 (15.2 %) 49 (36.0 %) ²P=0.008 
Non-HPV 18 A7 3 (6.5 %) 18 (12.9 %) ²P=0.220 
LR-HPV ⁶ 0 (0.0 %) 12 (8.8 %) ²P=0.040 
¹Chi-Square test, ²Fishers Exact test, ³High risk, ⁴ (16, 31, 33, 35, 52, and 58), ⁵ (18, 39, 
45, 59 and 68), 
 ⁶Low risk  
 
Table 8: Distribution of Alpha 9 and Alpha 7 types in cervical cancer specimens from 
Indiana and Botswana 
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Multiple HPV types 
A single HPV type was most often detected in cervical cancer specimens from 
both sites (Indiana and Botswana). One HPV type (vs. more than one type) was detected 
in 43 of 46 (93.5%) cervical cancer specimens from Indiana and 113 of 136 (83.1%) 
cervical cancer specimens from Botswana (p=0.603). Some cervical cancer specimens 
contained more than one HPV type (multiple HPV types). Multiple HPV types were 
detected in 3 of 46 (6.5%) cervical cancer specimens from Indiana (all 3 cervical cancer 
specimens were infected with 2 types) and 23 of 136 (17.0%) cervical cancer specimens 
from Botswana (19 were infected with 2 types, 2 infected with 3 types, 1 infected with 4 
total types, and 1 infected with 7 types). When HPV multiple types were compared 
between Indiana and Botswana, the difference was not statistically significant (p=0.603) 
(Table 9).  
 
Number of HPV types/case Indiana 
 (n=46) 
Botswana 
(n=136) 
p-value 
One type 43 (93.5%) 113 (83.1%)  
Two types 3 (6.5%) 19 (14.0%)  
Three types 0  2 (1.5%)  
More than three types 0 2 (1.5%) ¹p=0.603 
¹Chi-Square test 
Table 9: Multiple HPV types in cervical cancer from Indiana and Botswana 
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HIV detection  
HIV positivity 
All beta-globin positive cervical cancer specimens from Indiana and Botswana 
were tested for HIV (see methods). The HIV gag gene segment was amplified in 2 of 50 
(3.9%) cervical cancer specimens from Indiana and 54 of 171 (32.2%) cervical cancer 
specimens from Botswana (p<0.001) (Table 10).   
 
Study site Indiana  
(n=50) 
Botswana  
(n=171) 
p-value 
HIV-negative cases 
 
HIV-positive cases 
 
48 (96.0%) 
 
2 (3.9%) 
 
117 (68.4%) 
 
54 (31.6%) 
 
 
¹p<0.001 
 
 
¹Chi-Square test 
Table 10: HIV prevalence in cervical cancer specimens from Indiana versus Botswana 
HIV detection and its association with HPV type distribution in cervical 
cancer specimens from Botswana  
Analysis of the distribution of HPV-positive cervical cancer specimens between 
HIV-positive and HIV-negative cervical cancer specimens was done only for Botswana 
specimens in order to evaluate the association of HIV and HPV type distribution in 
Botswana.  This analysis was not performed on the cervical cancer obtained from Indiana 
due to the low prevalence of HIV based on results of PCR assay (Table 10). Overall, 44 
of 54 (81.5%) of HIV-positive cervical cancers from Botswana were HPV-positive and 
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92 of 117 (78.6%) of HIV-negative cervical cancers from Botswana were HPV-negative. 
Among HIV-positive cervical cancer specimens from Botswana, HPV 16 was detected in 
20 of 44 (45.5%) and 38 of 92 (41.3%) were HPV 16-positive among the HIV-negative 
cervical cancer specimens from Botswana (p=0.647) Table 11. Eight of 44 (18.2%) of 
HIV-positive cervical cancer specimens from Botswana, and 24 of 92 (26.1%) of HIV-
negative cervical cancer specimens from Botswana were positive for HPV 18 (p=0.309) 
Table 11. Four of 44 (9.1%) of HIV-positive cervical cancer specimens from Botswana, 
and 1 of 92 (1.1%) of HIV-negative cervical cancer specimens from Botswana were HPV 
31-positive (P=0.038) Table 11.  
HIV detection and its association on detection of Alpha 9 and Alpha 7 HPV 
types in cervical cancer specimens from Botswana  
Also, Table 11 shows HPV types divided into different groups as a function of 
HIV status. Among HIV-positive cervical cancer specimens from Botswana, HR-HPV 
types were detected in 41 of 44 (93.2%). And among HIV-negative cervical cancer 
specimens from Botswana, HR-HPV types were detected in 89 of 92 (96.7%) (p=0.388). 
Four of 44 (9.4%) of HIV-positive cervical cancer specimens from Botswana, and 8 of 92 
(8.7%) HIV-negative cervical cancer specimens from Botswana contained LR-HPV types 
(p=1.00). Among HIV-positive and HIV-negative cervical cancer from Botswana, non-
HPV 16/18 (p=0.765), non-HPV 16/18 HR-HPV (p=0.677), A9 types (p=0.201), non-
HPV 16 A9 types (p=0.459), A7 types (p=0.276), and non-HPV 18 types (p=0.656) did 
not differ significantly (Table 11).  
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  HIV-positive 
(n=44) 
HIV-negative 
(n=92) 
p-value 
 
HR-HPV1 
 
   
 41 (93.2%) 
 
89 (96.7%) 
......... 
 
p=0.388 
LR-HPV2   4 (9.1%) 8 (8.7%) p=1.000 
 
Non-HPV 16/18  
  
 20 (45.5%) 
 
45 (48.9%) 
 
p=0.706 
 
Non-HPV 16/18 HR  
  
17 (38.6%) 
 
39 (42.4%) 
 
p=0.677 
     
A9 Types3   
 
29 (65.9%) 50 (54.4%) p=0.201 
HPV 16-Positive  20 (45.5%) 38 (41.3%) p=0.647 
 
Non-HPV 16 A9 
Types 
  
10 (22.7%) 
 
16 (17.4%) 
 
p=0.459 
 
A7 Types4 
  
13 (29.6%) 
 
36 (39.1%) 
 
p=0.276 
 
HPV 18-positive 
 
 
 
8 (18.2%) 
 
24 (26.1%) 
 
p=0.309 
 
Non-HPV 18 A7 
Types 
  
5 (11.4%) 
 
13 (14.1%) 
 
p=0.656 
     
     
 
1HR-HPV= High-risk HPV types, 2LR-HPV= Low-risk HPV types, 3A9 types= HPV 
types 16, 31, 33, 35, 52, and 58;  
4A7 types= HPV types 18, 39, 45, 59, and 68; 5Fisher’s exact test; 6Chi-square test.    
 
Table 11: HPV type distribution among HIV-positive and HIV-negative in Botswana 
cervical cancers  
 
HIV and multiple HPV types 
We also examined the association of multiple HPV types with HIV in cervical 
cancer specimens from Botswana. Multiple HPV types were detected in 5 of 44 (11.4%)  
HIV-positive cervical cancer specimens from Botswana, and 18 of 92 (19.6%) HIV-
negative cervical cancer specimens from Botswana (p=0.232).  
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Discussions 
Quality of extracted DNA from cervical cancer from Indiana and Botswana 
The first objective of this study was to determine if high quality DNA could be 
extracted from FFPE cervical cancer specimens from Indiana and Botswana. Base on 
beta-globin positivity in specimens from Indiana (98%) and Botswana (94.2%) (Data 
shown in table 5) it is clear that we were able to extract high quality DNA.   
Archived FFPE of cervical cancer specimens represent an easily obtainable source 
for HPV evaluation for many reasons: 1) FFPEs are widely available; 2) they are easy to 
store and 3) easy to transport. However, many challenges arise when extracting high 
quality DNA from FFPE tissues. DNA in FFPE tissues degrades, denatures and cross-
links with cellular proteins. This is due to long incubation of tissue in formalin prior to 
fixation, inappropriate storage conditions (high temperature), using high concentration of 
formalin, and using low pH formalin 50,51. These factors affect primarily the size of 
extracted DNA fragments, which in turn affects downstream applications such as PCR. It 
had been reported in a number of studies that extracted DNA from FFPE specimens 
amplify only shorter DNA fragments (less than 200 bp) 52-54. 
In this study we were able to amplify 300 bp beta-globin fragments and 450 bp 
HPV L1 sequences using extracted DNA from FFPE of cervical cancer specimens from 
Indiana and Botswana.  Our success in extracting good quality DNA was due to 
development of a protocol based on three steps. First, we removed paraffin in which the 
archived tissue was stored using octane. This step was very essential in removing PCR 
inhibitors from the stored tissues as Santa et al., described 55. Second, we digested the 
tissue with proteinase K in STM. To the best of our knowledge, this is the first time that 
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STM was used as buffer for proteinase K during FFPE tissue digestion. We believe that 
STM is very stable buffer that maximizes proteinase K activity. Also, this might play a 
role in removing inhibitors released during tissue digestion such as formalin. Since STM 
components are not published, we can’t prove these speculations biochemically. Yet, we 
chose to use STM instead of regular digestion buffer (composed of Tris-HCL, EDTA and 
NaCl) mainly based on our experience. In numerous epidemiologic studies were 
conducted in our laboratory in which we substituted regular digestion buffer with STM, 
we observed that beta-globin positivity increased from approximately 92% to 99% 56.   
The increase in beta-globin positivity was most due to the use of STM. Third, we 
extracted DNA using QIAamp MinElute Media Kit. To the best of our knowledge this is 
the first time that this kit was used in DNA extraction from FFPE tissues. This kit had 
been demonstrated in isolating DNA from cervical and vaginal swabs in a number of 
studies conducted in our laboratory to optimize the recovery of good quality DNA and 
eliminate PCR inhibitors 57-59. QIAamp MinElute Media Kit extracts DNA based on the 
silica-based membrane DNA binding mechanism. The silica-based membrane captures 
the DNA and allows for washes for removing most of contaminant molecules. As a result, 
high quality DNA was extracted. The average 260:280 ratios (quality) of extracted DNA 
using this kit show good values (>1.8).   
HPV typing of cervical cancer specimens from Indiana and Botswana 
The second objective of this study was to amplify and type HPV DNA from 
cervical cancer specimens from Indiana and Botswana. Overall, the prevalence of HPV 
DNA positivity from Indiana and Botswana was respectively 92.0% and 79.5%, which is 
similar to that found in other studies 60-63. However, a significant difference in HPV 
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positivity was found between cervical cancer specimens from Indiana and Botswana 
(P=0.042).  There are several possible reasons for this difference. First, integration of the 
HPV genome into the host genome most often leads to the disruption of the E2 gene but 
also can occur in HPV L1 gene 26. Thus, L1 cannot be amplified in such cases. 
Supporting this hypothesis, in a comparison of MY09/11(target L1 gene) 
consensus PCR and type specific PCR (target E6/E7 genes), Depuydt et al. shown an 
increase of 10% in HPV DNA detection when type specific E6/E7 PCR was used to test 
HPV DNA negative specimens from MY09/11 consensus PCR 64. Since the LA-HPV 
used in this study tests only for L1 gene, however, the HPV DNA negative result in 
cervical cancer specimens from Botswana could be contributed to the loss of HPV L1 
gene during integration in host genome.  
Second, it is possible that the integrity of extracted DNA from samples from 
Indiana exceeds that of specimens from Botswana, which may have been subjected to 
prolonged fixation in formalin. Lastly, it is possible that Botswana cervical cancer 
specimens contain a lower HPV viral load than Indiana cervical cancer specimens, so that 
the sensitivity of the PCR/typing assay may not detect HPV in as many Botswana 
specimens. 
Our success in amplifying and typing HPV DNA from cervical cancer specimens 
from Indiana and Botswana validates a method for HPV DNA detection from archival 
cervical cancer specimens. This adds another method that detects HPV DNA directly 
from cervical cancer specimens instead of relying on data obtained from cervical swabs. 
As discussed above, cervical swabs may contain many HPV types that may not represent 
the types causing the cervical cancer. 
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Comparison of HPV type distribution in cervical cancer specimens from Indiana 
and Botswana 
To investigate the impact of geographical variation in the distribution of HPV 
types in Indiana and Botswana, we compared cervical cancer specimens from Indiana and 
Botswana.  
Our results showed that HPV 16 was most commonly detected HPV type in 
cervical cancer specimens from Indiana. HPV 16 prevalence in cancers from Indiana was 
87%, a higher figure compared to the international average for HPV 16 detection in 
invasive cervical cancer, which is approximately 53% 65.  This international average of 
HPV 16 prevalence was established based on a meta-analysis study by Clifford et al. in 
2007 , in which cervical cancer data from 130 studies conducted in Africa, Asia, Europe, 
North America and South America was analyzed 66. Clifford et al. showed that HPV 16 
prevalence in cervical cancers from North America was approximately 55%. This meta-
analysis included studies that utilized exfoliated cells instead of cervical cancer tissues, 
and used a variety of PCR methods.  In contrast, our study utilized FFPE cervical cancer 
specimens with a validated HPV typing method, and likely provides a good estimate of 
the prevalence of HPV 16 in cervical cancers from Indiana.   
HPV 16 was also the most frequently detected HPV type in cervical cancers from 
Botswana. The overall frequency of HPV 16 detection in cancers from Botswana was 
42.7%.  The prevalence of HPV 16 reported by Odida et al. (47.8%) was similar to what 
we demonstrated in cancers from in Botswana 67. Similar to our study, the analysis by 
Odida et al. used FFPE cervical cancer specimens with a validated HPV typing method.  
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HPV type 18 was the second most frequently detected HPV type in Indiana. Our results 
showed that HPV 18 prevalence was 8.7%. This result is in accordance with the 
international average for HPV 18 detection in invasive cervical cancers in North America, 
which is approximately 12% 66,68. The prevalence of HPV 18 detected in cancers from 
women living in Indiana was lower than that found in cervical cancers from Botswana. 
We found that HPV 18 was the most common HPV type detected in cervical cancer from 
Botswana, which is 23.5%. This result was similar to that reported by Odida et al. in the 
Uganda study mentioned above (22.8%) 67. However, the overall prevalence of the two 
major HPV types combined (HPV types 16 and 18) detected in cancers from Indiana, 
(93.5%), was significantly higher than combined frequency of HPV 16 and 18 in cervical 
cancers from Botswana (61.8%).  
After HPV 16 and 18, HPV 45 was the third most common HPV type in cervical 
cancers from Indiana and Botswana, detected in 6.5% of cervical cancers from Indiana 
and 8.8% in cervical cancers from Botswana. Our results are consistent with previous 
studies, which showed that HPV 45 was detected 6% in cervical cancers from North 
America and 10% in cervical cancers from Africa 69,70. In addition to HPV types 16, 18 
and 45, we detected only two additional HPV types, which are HPV 31 and 33, in 
cervical cancer from Indiana with a low prevalence of 2.2%. However, other 
investigators found additional HR-HPV types other than HPV types 16, 18, 45, 31 and 
33. For example de Sanjose et al. identified other HR-HPV types such as HPV types 34, 
39, 51, 52, 53, 56 and 58 in North America 70. These additional HR-HPV types 
contributed small percentage to the overall HPV found in North America. We did not 
detect these additional HR-HPV types in cervical cancer from Indiana in our study. This 
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may be due the fact that our results were based on relatively small number of cervical 
cancer cases from Indiana or we used in this study different DNA extraction and HPV 
detection methods.  
Since HPV types 16 and 18 were less often found in cervical cancers from 
Botswana, what HPV types were more abundant in these specimens? We examined the 
distribution of non-HPV 16/18 HR types in cervical cancers.  Overall, non-HPV 16 A9 
family members (HPV types 31, 33, 35, 52, and 58) were significantly more frequently 
detected in cancers from women living in Botswana.  In contrast, non-HPV 18 A7 family 
members (HPV types 39, 45, and 68) were found with the same frequency in cancers 
from women living in Indiana or Botswana. 
Our findings have shown different HPV type distribution patterns in Indiana 
compared to Botswana. This has implications with regard to HPV vaccine 
recommendations. The available HPV vaccines, which protect against HR-HPV types 16 
and 18, may provide higher protection from cervical cancer to women from Indiana than 
to women in Botswana.  
HIV infection and HPV type distribution in Botswana 
What factors could contribute to these differences in HPV type distribution 
between Indiana and Botswana?  HIV infection is one possible factor, as HIV infection 
increases the relative risk of cervical cancer 71-74. Because HIV infection is prevalent in 
women living in Botswana (see the section on rationale), HPV detection was compared in 
HIV-positive and HIV-negative cervical cancer specimens from Botswana.   Due to the 
low HIV positivity in Indiana specimens, we focused our analysis on Botswana 
specimens only.  Our results show that the distribution between HPV types and groups of 
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HPV types was similar in women who were HIV-negative and HIV-positive, except for 
HPV 31, which was found more frequently in HIV-positive women than HIV-negative 
women from Botswana.  Therefore, our study did not support the hypothesis that HIV 
infection is a major factor that influences distribution of HPV types in Botswana.  
However, it cannot eliminate completely HIV as a factor driving some differences. This 
could be attributed to some limitations of this study including small size samples and 
unavailability of HIV serological data from Botswana. Due to the low number of HIV 
positive cervical cancers from Indiana, our ability to compare HPV type distribution 
among HIV positive specimens from both sites was limited.  
Also, due the lack of serological data from Botswana, we developed a unique 
method to amplify HIV pro-viral DNA from paraffin-embedded tissues to determine the 
HIV status of these women (see method section). However, the sensitivity of this method 
has not been determined.  Therefore, a larger cervical cancer study with high HIV 
prevalence in which serologic data for HIV-positivity is known, and could reveal the true 
impact of HIV infection on type differences in cervical cancers. Other factors may be 
considered in future studies include geographical variation, nutritional factors and co-
infections with certain pathogens commonly found in Botswana.  
Other limitations to the current study should also be considered. The archived 
paraffin-embedded cervical cancers we used in this study may reduce the sensitivity for 
HPV detection compared to fresh cervical cancer tissues, as has been shown in a study by 
Odida et al. 62.  Moreover, our results are specific to cervical cancer in Indiana and 
Botswana, and cannot necessarily be generalized to other populations.  
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Conclusions 
• High quality DNA was extracted from FFPE cervical cancer specimens from 
Indiana and Botswana.  
• The prevalence of HPV types 16 and 18 was significantly higher in cervical 
cancers from women living in Indiana compared to cervical cancers from women 
living in Botswana. Oncogenic types other than HPV 16 or HPV 18 were more 
frequently detected in cervical cancers from women living in Botswana.  
• Multiple HPV types were not frequently identified in individual cases of cervical 
cancers from either country.  
• HIV status appeared to have a modest effect on HPV type distribution in cervical 
cancers from women living in Botswana, but the test utilized to determine HIV 
status in these women has not yet been validated.   
• The current HPV vaccines, which protect from HPV16 and HPV 18, may provide 
protection from cervical cancer to a higher degree in women living in the U.S. 
compared to women living in Botswana. Therefore, even if widely used in a 
vaccination program, a substantial percentage of women from Botswana may still 
remain at risk of cervical cancer from the other HR-HPV types. Second 
generation HPV vaccines that provide protection against oncogenic HPV types in 
addition to HPV 16 and HPV 18 may be better suited for Botswana.  Further 
studies are needed to determine if the findings described here are generalizable to 
other sub-Saharan countries.  
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